BiotechTube

BIIB104

Phase 2Completed
0 watching 0 views this week⚡ Active
49
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Cognitive Impairment Associated With Schizophrenia

Conditions

Cognitive Impairment Associated With Schizophrenia

Trial Timeline

Nov 15, 2018 → Apr 7, 2022

NCT ID
NCT03745820

About BIIB104

BIIB104 is a phase 2 stage product being developed by Biogen for Cognitive Impairment Associated With Schizophrenia. The current trial status is completed. This product is registered under clinical trial identifier NCT03745820. Target conditions include Cognitive Impairment Associated With Schizophrenia.

Hype Score Breakdown

Clinical
17
Activity
12
Company
7
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT03745820Phase 2Completed

Competing Products

20 competing products in Cognitive Impairment Associated With Schizophrenia

See all competitors
ProductCompanyStageHype Score
Aricept (donepezil hydrochloride) + placeboEisaiApproved
85
DonepezilEisaiApproved
85
AriceptEisaiPhase 2
52
Donanemab + AducanumabEli LillyPhase 3
77
ABT-126 + PlaceboAbbViePhase 2
52
SDI-118 + PlaceboAbbViePhase 1
33
ABT-288 Low Dose + Placebo + ABT-288 High DoseAbbViePhase 2
52
AZD5213 + AZD5213 + AZD5213AstraZenecaPhase 2
52
MK-8931MerckPhase 1
33
Nicotine patch + MK-4334 + Placebo patch + Placebo capsuleMerckPhase 1
33
Verubecestat 12 mg (Parts 1 and 2) + Verubecestat 40 mg (Parts 1 and 2)MerckPhase 3
77
RivastigmineNovartisPhase 3
77
RivastigmineNovartisApproved
85
Exelon (rivastigmine) + PlaceboNovartisApproved
85
CanakinumabNovartisPhase 2
52
EvipleraGilead SciencesApproved
84
atorvastatinPfizerPre-clinical
22
bosutinibPfizerPhase 1
32
Aducanumab + PlaceboBiogenPhase 2
49
BIIB080 + BIIB080-matching placeboBiogenPhase 2
49

Other Products from Biogen

Interferon-beta-1a + methylprednisoloneApproved
82
Dimethyl fumarateApproved
82
[18F]Florbetapir PET imagingApproved
82
dimethyl fumarateApproved
82
ibritumomab tiuxetan (Zevalin®)Approved
82